Bayer's Legal and Clinical Crucible: A Fortnight of Fate

Bayer faces a pivotal 10 days with a U.S. Supreme Court hearing on Roundup lawsuits and positive Phase III data for its key drug asundexian, alongside its AGM.

Investors in Bayer AG are bracing for a pivotal ten-day stretch, with a landmark U.S. Supreme Court hearing and a major shareholder meeting set to define the German conglomerate’s near-term trajectory. The equity, trading around €40.55, has staged a remarkable recovery, surging over 94% in the past twelve months from a low below €22. Yet this rally now faces a critical test of its foundations.

All eyes are on Washington, D.C., where the Supreme Court will hear arguments on April 27. The case centers on whether the federal pesticide law, FIFRA, preempts state-level warning requirements for products like glyphosate. Bayer’s position is that manufacturers owe no warnings beyond federal mandates. A favorable ruling for the company could strip tens of thousands of ongoing Roundup lawsuits of their legal basis, potentially removing a multi-year overhang that has weighed heavily on the stock’s valuation and sentiment.

Simultaneously, the company’s pharmaceutical division has delivered significant clinical news, marking a strategic comeback. On April 16, the New England Journal of Medicine published full Phase III results for the investigational drug asundexian from the OCEANIC-STROKE trial. The data, involving 12,327 patients across 37 countries, showed the Factor XIa inhibitor reduced the risk of ischemic stroke by 26% compared to placebo, with no associated increase in bleeding risk. In the trial, 6.2% of patients on asundexian suffered a subsequent stroke, versus 8.4% in the placebo group.

This outcome is crucial for Bayer’s growth plans. With blockbuster anticoagulant Xarelto facing patent expiry, the company urgently needs a successor to drive its pharmaceuticals business, which has seen stagnating sales. Asundexian is a cornerstone of Bayer’s strategy to return the division to mid-single-digit growth from 2027 onward. The successful data represents a reversal of fortune after the company was forced to halt the related OCEANIC-AF study three years ago due to lack of efficacy.

Corporate governance is also in focus. The registration period for Bayer’s Annual Stockholders’ Meeting closes today. The virtual meeting on April 24 will see shareholders vote on discharging the management and supervisory boards, elect two new supervisory board members—Marcel Smits and Alfred Stern, replacing Paul Achleitner and Colleen Goggins—and approve a dividend proposal of €0.11 per share for fiscal 2025. Management is expected to provide further details on the asundexian regulatory strategy during the event.

The stock’s technical picture shows a mixed near-term signal. While the share price holds a solid 19% premium above its 200-day moving average, it currently trades just below the 50-day average of €41.19. Analyst sentiment remains cautious; Deutsche Bank recently reiterated its "Hold" rating without specifying a price target.

For Bayer, the coming fortnight encapsulates its dual challenge: navigating a legacy legal quagmire while proving its pipeline can deliver future growth. The Supreme Court’s deliberation and the clinical pathway for asundexian will together determine whether the stock’s impressive recovery is built to last.